Document:

EX-4.4

 Exhibit 4.4 

DATED AUGUST 28, 2020 

between 
 GLOBAL BLUE GROUP
HOLDING AG 
 and 
 SL
GLOBETROTTER L.P. 
  
  

RELATIONSHIP AGREEMENT 
  

 
  

 THIS RELATIONSHIP AGREEMENT (the “Agreement”) is made on August 28, 2020 

BETWEEN: 
  

	(1)	 GLOBAL BLUE GROUP HOLDING AG, a limited company having its registered office in Zurichstrasse 38,
8306 Bruttisellen, Aktiengesellschaft (Neueintragung), Switzerland and identification number UID 442.546.212 (the “Company”); and 

  

	(2)	 SL GLOBETROTTER L.P., an exempted limited partnership formed under the laws of the Cayman
Islands, having its registered office at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and registered in the Cayman Islands General Registry
(the “SL Institutional Shareholder”). 

 The parties to this Agreement are hereinafter collectively
referred to as the “Parties” and individually as a “Party”. 
 RECITALS: 

 

	(A)	 Following the closing (the “Closing”) of a merger agreement by and among, inter alia, the
Company and the Seller Parties (as defined therein), entered into on or around the date hereof (the “Merger Agreement”), the Company will own the business known as ‘Global Blue’ and the Common Shares (as defined below) of
the Company will be listed on the New York Stock Exchange (the “Exchange”). 

  

	(B)	 Following Closing, the SL Institutional Shareholder will own certain Company Securities. 

 

	(C)	 The Parties and Far Point LLC entered into a relationship agreement (the “Original RA”) on
January 16, 2020, and by letter agreement dated August 15, 2020, the Parties and Far Point LLC agreed that Far Point LLC would thereby be released from its liabilities and obligations, and would thereby cease to have any rights or
benefits, under the Original RA and would thereby cease to be a party to the Original RA. 

  

	(D)	 The Parties, as the sole parties to the Original RA as amended, have agreed to enter into this amended and
restated agreement to regulate the relationship between them and to govern the exercise by the SL Institutional Shareholder of its rights in respect of the Company and to amend and restate the Original RA which will be superseded in its entirety by
this Agreement. 

 IT IS AGREED as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 The following terms shall, unless the context otherwise requires, have the following meaning:

 “Affiliate” means with respect to a Person (the “First Person”): 

 

	 	(i)	 another Person that, directly or indirectly through one or more intermediaries, Controls, or is Controlled by,
or is under common Control with, the First Person; 

  

	 	(ii)	 a pooled investment vehicle organised by the First Person (or an Affiliate thereof) the investments of which
are directed by the First Person (or an Affiliate thereof); 

  

	 	(iii)	 a fund organised by the First Person for the benefit of the First Person’s (or any of its
Affiliates’) partners, officers or employees or their dependants; or 

  

	 	(iv)	 a successor trustee or nominee for, or a successor by reorganization of, a qualified trust (being a tax
advantaged fiduciary relationship between an employer and an employee in which the employee beneficiary may use his life expectancy to determine required minimum distribution amounts), 

 but shall, where applicable, exclude portfolio companies controlled by funds managed
directly or indirectly by Silver Lake Technology Management, L.L.C., or Partners Group or portfolio companies managed directly or indirectly by Persons falling within limb (i) above in respect of any of them and any of their respective
partners, officers, employees or their dependents; 
 “Ant Board Member” means a member of the Board designated by the SL
Institutional Shareholder in accordance with Clause 3.2.12; 
 “Ant Institutional Shareholder” means Antfin (Hong Kong)
Holding Limited; 
 “Articles” means the articles of association of the Company as amended from time to time in accordance
with the Board Rules; 
 “Board” means the board of the Company, as constituted from time to time; 

“Board Committees” means the finance and audit committee and the nomination and compensation committee of the Board, and any
other committees which the Board may have from time to time; 
 “Board Committee Rules” means the charters of the Board
Committees as amended from time to time in accordance with the Board Rules; 
 “Board Meeting” means the board meeting of
the Board Members; 
 “Board Member” means a member of the Board; 

“Board Rules” means the organizational regulations of the Board as amended from time to time in accordance with their terms;

 “Business Day” means any day, except a Saturday or Sunday or English bank or public holiday in the Cayman Islands,
London, New York or Switzerland; 
 “Closing” has the meaning given thereto in the recitals of this Agreement; 

“Code of Best Practice” means the Swiss Code of Best Practice for Corporate Governance; 

“Common Shares” means the registered common shares with a nominal value of CHF 0.01 each of the Company (or any successor of
the Company by combination of shares, recapitalization, merger, consolidation or other reorganization) and any shares into which any such Common Shares shall have been changed or any shares resulting from any reclassification of any such Common
Shares; 
 “Company” has the meaning given thereto in the recitals of this Agreement; 

“Company Securities” means, together, the (i) Common Shares, (ii) Series A Preferred Shares and (iii) Warrants;

  
 3 

 “Confidential Information” means any information of a secret or
confidential nature concerning the Global Blue Group received at any time prior to or after the date of this Agreement, but excluding any information which: 

	 	(i)	 was in the possession of or was known to any member of the SL Institutional Shareholder’s Group prior to
its receipt from the Global Blue Group (other than through a breach of Clause 5 of this Agreement); 

  

	 	(ii)	 was or is independently developed by any member of the SL Institutional Shareholder’s Group without the
utilization of such Confidential Information; 

  

	 	(iii)	 is or becomes public knowledge without the fault of any member of the SL Institutional Shareholder’s
Group; or 

  

	 	(iv)	 is or becomes available to any member of the SL Institutional Shareholder’s Group from a source other than
the Global Blue Group in circumstances where any member of the SL Institutional Shareholder’s Group is not aware that disclosure has been made in breach of an obligation of confidentiality; 

“Control” means, with respect to a Person (other than an individual) (a) direct or indirect ownership of more than 50% of
the voting securities of such Person, (b) the right to appoint, or cause the appointment of, more than 50% of the members of the board of directors (or similar governing body) of such Person or (c) the right to manage, or direct the
management of, on a discretionary basis, the assets of such Person, and, for the avoidance of doubt, a general partner is deemed to Control a limited partnership and, solely for the purposes of this Agreement, a fund advised or managed directly or
indirectly by a Person shall also be deemed to be Controlled by such Person (and the terms “Controlling” and “Controlled” shall have meanings correlative to the foregoing); 

“Deed of Accession” means a deed of accession to this Agreement in the form attached as Schedule 1 (Deed of Accession) hereto;

 “Dispute” has the meaning given thereto in Clause 9.9 of this Agreement; 

“Executive Board Member” means a member of the Board who is an executive of the Global Blue Group from time to time and being,
as at the date hereof, Jacques Stern; 
 “Exchange” has the meaning given thereto in the recitals of this Agreement; 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and
Exchange Commission promulgated thereunder; 
 “General Meeting” means the general meeting of shareholders of the Company;

 “Global Blue Group” means the Company, its group companies and its direct and indirect subsidiaries; 

“Group” means: 
  

	 	(i)	 in the case of the SL Institutional Shareholder, the SL Institutional Shareholder and Partners Group, and each
of their respective Affiliates, but excluding the Global Blue Group; or 

  

	 	(ii)	 in the case of the Ant Institutional Shareholder, the Ant Institutional Shareholder and each of its direct and
indirect subsidiary undertakings; 

 “Independent Board Member” means a member of the Board who is
considered by the Company to be independent in accordance with the requirements of the Exchange (including, in the context of members of the finance and audit committee, under Rule 10A-3 under the Exchange
Act, as applicable) and the standards of independence promulgated by the Board from time to time; 

  
 4 

 “Information” has the meaning given thereto in Clause 5.1 of this
Agreement; 
 “Institutional Shareholder Board Member” means a member of the Board designated by the SL Institutional
Shareholder in accordance with Clause 3.2.1 or 3.2.2; 
 “Management Information Package” means a package of information
relating to the Global Blue Group made up to, and as at the end of, the relevant calendar month, in such form as has been produced in the six months prior to the date of this Agreement or as subsequently specified by the Board but at least
incorporating a profit and loss account, balance sheet and cash flow statement for the Global Blue Group on a monthly basis and year-to-date basis together with a
breakdown identifying variances from the Global Blue Group’s annual operating budget and the prior year figures and showing annual totals for Sales-in-Store,
revenue, and EBITDA; 
 “Merger Agreement” has the meaning given thereto in the recitals of this Agreement; 

“Parties” has the meaning given thereto in the recitals of this Agreement; 

“Partners Group” means Partners Group Client Access 5, L.P. Inc., Partners Group Private Equity (Master Fund), LLC, and
Partners Group Barrier Reef, L.P.; 
 “Person” means a natural person, partnership, corporation, limited liability company,
business trust, joint stock company, trust, unincorporated association, joint venture or other entity or organization; 
 “Series A
Preferred Shares” means the registered series A convertible preferred shares with a nominal value of CHF 0.01 each of the Company (or any successor of the Company by combination of shares, recapitalization, merger, consolidation or other
reorganization) and any share into which any such Series A Preferred Shares shall have been changed or any shares resulting from any reclassification of any such Series A Preferred Shares; 

“SL Board Member” means a member of the Board designated by the SL Institutional Shareholder in accordance with Clause 3.2.1;

 “SL Institutional Shareholder” has the meaning given thereto in the recitals of this Agreement; 

“Takeover Offer” means a public takeover offer for all or part of the Common Shares; 

“Voting Shares” means, together, the Common Shares and the Series A Preferred Shares. 

 

	1.2	 In this Agreement, unless the context dictates otherwise: 

 

	 	(i)	 the masculine gender shall include the feminine and the neuter and vice versa and references to the singular
shall include the plural and vice versa; 

  

	 	(ii)	 references to “include” and “including” shall be treated as references to “include
without limitation” or “including without limitation”; 

  

	 	(iii)	 the headings are for identification only and shall not affect the interpretation of this Agreement; and

  
 5 

	 	(iv)	 references to any statute or statutory provision include any code, regulation, statute or statutory provision
which amends, extends, consolidates or replaces the same, or which has been amended, extended, consolidated or replaced by the same, and shall include any orders, regulations, instruments or other subordinate legislation made under the relevant
statute or statutory provision. 

  

	2.	 CONDITIONALITY 

 

	2.1	 Subject to Clause 2.3, this Agreement is conditional upon Closing occurring in accordance with the terms of the
Merger Agreement and shall become effective upon Closing and shall thereafter continue to be effective until terminated in accordance with Clause 7 (Termination). 

 

	2.2	 In the event that the Merger Agreement is terminated without Closing occurring, this Agreement shall cease and
be of no further effect. 

  

	2.3	 This Clause 2.3 takes effect immediately notwithstanding Clause 2.1 and the Parties agree that this Agreement
supersedes in its entirety the Original RA. 

  

	3.	 BOARD 

  

	3.1	 The Parties acknowledge and agree that the Board shall include at least three members who qualify as
Independent Board Members and the chairperson of the Board shall at all times be a non-executive Board Member. The Board shall not at any time have more than one executive Board Member, if any, and if there is
an executive Board Member, this shall be the chief executive officer of the Global Blue Group. 

  

	3.2	 Subject to Clause 3.6: 

 

	 	3.2.1	 the SL Institutional Shareholder shall have the right to designate up to three persons for nomination by the
Board as SL Board Members and to designate replacements for such SL Board Members; and 

  

	 	3.2.2	 the SL Institutional Shareholder shall have the right to designate an additional one person for nomination by
the Board at or prior to Closing as the Ant Board Member, 

 who, in each case, in the reasonable assessment of the Board,
satisfy any applicable requirements imposed by the Articles, Board Rules, Board Committee Rules and any other corporate governance policies that are applicable to Board Members generally. It is understood and agreed that in no event shall such
persons’ affiliation with the SL Institutional Shareholder or the Ant Institutional Shareholder (as applicable) make such persons ineligible to be members of the Board. Such persons will not need to be ‘independent’ for purposes of
the Code of Best Practice or pursuant to Rule 10A3 under the Exchange Act. 
  

	3.3	 If, and at any time, the SL Institutional Shareholder has the right to designate a representative for
nomination by the Board as a Board Member pursuant to Clause 3.2, the Company shall, following the assessment by the Board pursuant to the preceding paragraph, procure that the Board nominates the person designated by the SL Institutional
Shareholder for election as a Board Member and to use reasonable efforts to procure the election of the person designated by the SL Institutional Shareholder to the Board at each relevant General Meeting, including by soliciting the vote of the
Shareholders to vote in favour of Board nominees and providing any other support that the Company or the Board provides to any other nominees to the Board. 

  
 6 

	3.4	 If, and at any time, the SL Institutional Shareholder has the right to designate a representative for
nomination by the Board as a Board Member pursuant to Clause 3.2: 

	 	(i)	 in the case of (i) the removal, resignation, retirement, death or disability of its relevant Board Member
or (ii) the failure of the person designated by the SL Institutional Shareholder to be nominated for election to the Board at any General Meeting, the SL Institutional Shareholder shall have the right, but not the obligation, to submit in
writing to the Company a nomination for a replacement representative to the Board; and 

  

	 	(ii)	 the Company agrees to nominate the person designated by the SL Institutional Shareholder as a new Board Member
and undertakes to promptly call and hold an extraordinary General Meeting with the agenda item to elect the proposed person as a new Board Member. 

Until the Institutional Shareholder Board Member is elected, the SL Institutional Shareholder who designated such Institutional Shareholder
Board Member will have the right, but not the obligation, to designate a representative to attend, as an observer, the (x) meetings of the Board and (y) committees of the Board (only to the extent the SL Institutional Shareholder had the
right to designate a Board Member to such committee) and, as an observer, the SL Institutional Shareholder’s representative shall (i) be entitled to participate, without voting rights, in all (x) Board and (y) committee (only to
the extent the SL Institutional Shareholder had the right to designate a Board Member to such committee) meetings; (ii) receive the same information and materials as the other Board Members; (iii) be invited to meetings at the same time as
the other directors; and (iv) be entitled to the same expense reimbursement as the other directors, in each case to the extent permitted under applicable law. Such observer may share information as though Clause 3.7 applied but subject to any
directions or restrictions determined by the Board from time to time. 
  

	3.5	 If, and at any time, the SL Institutional Shareholder has the right to nominate a representative to the Board
pursuant to Clause 3.2, the SL Institutional Shareholder shall be entitled to require that its representative not be nominated for re-election at the next annual General Meeting or that the Company convene an
extraordinary General Meeting to effect the dismissal of such representative from the Board. 

  

	3.6	 The SL Institutional Shareholder’s right under Clause 3.2.1 to designate for nomination by the Board
persons as SL Board Members, and to propose replacements for SL Board Members, shall be varied in accordance with the following provisions: 

  

	 	3.6.1	 if the SL Institutional Shareholder’s Group directly or indirectly holds less than 20% of the Voting
Shares (from time to time), the SL Institutional Shareholder will have the right to designate only two persons for nomination by the Board as SL Board Members; 

 

	 	3.6.2	 if the SL Institutional Shareholder’s Group directly or indirectly holds less than 10% of the Voting
Shares (from time to time), the SL Institutional Shareholder will have the right to designate only one person for nomination by the Board as a SL Board Member provided that this Clause 3.6.2 will only apply from the expiry of two years
following Closing; and 

  

	 	3.6.3	 if the SL Institutional Shareholder’s Group directly or indirectly holds less than 5% of the Voting Shares
(from time to time), the SL Institutional Shareholder shall not have the right to designate any persons for nomination by the Board as a SL Board Member provided that this Clause 3.6.3 will only apply from the expiry of two years following
Closing. 

  
 7 

	3.7	 The Parties acknowledge that where an Institutional Shareholder Board Member receives (i) in a capacity
other than that of a member of the Board, information which imposes on him or her a duty of confidentiality, he or she shall not be obligated to disclose that information to the Company or to the Board, and (ii) subject to Clause 5, any
information relating to the Company or the Global Blue Group (in his or her capacity as a member of the Board or otherwise), the Institutional Shareholder Board Member may, subject to his or her fiduciary duties and statutory obligations as a member
of the Board and subject to any restrictions under applicable law and provided that where such information is subject to legal privilege only to the extent that legal privilege is maintained, communicate such information to any member of the SL
Institutional Shareholder’s Group, provided that any such information so communicated shall be subject to Clauses 5.6 and 5.7. 

  

	3.8	 The Company and the Board shall be permitted to withhold from the Ant Board Member any Confidential Information
relating to commercial relationships between any member of the Global Blue Group, on the one hand, and the Ant Institutional Shareholder or its affiliates, on the other hand (including the strategic business cooperation agreement contemplated
between Global Blue SA and Alipay.com Co., Ltd or any of its affiliates), and any other Confidential Information which the Company reasonably determines is commercially sensitive, taking into account such commercial relationships. Upon the request
of any other Board Member, the Ant Board Member shall be recused from any meeting (or part thereof) during which any such Confidential Information or commercial relationships are to be disclosed to or discussed by the Board. 

 

	3.9	 Each Institutional Shareholder Board Member and any observer appointed pursuant to Clause 3.4 will be covered
by: (a) (irrespective of any separate insurance arranged by the SL Institutional Shareholder’s Group) the Company’s directors’ and officers’ liability insurance during their appointment and for a period of at least four years
following the date of their resignation or removal from the Board and (b) the Company’s indemnity policy during their appointment and for a period of at least six years following the date of their resignation or removal from the Board, in
each case on terms at least as favourable to the Institutional Shareholder Board Member or observer (as applicable) as the insurance and indemnity policy in place at the date of Closing, in the case of insurance where such insurance is then
reasonably commercially available. The terms of the Company’s directors’ and officers’ liability insurance, the Company’s indemnity policy any other relevant policy of insurance or other policy will remain at all times available
to the SL Institutional Shareholder from the Company on request. 

  

	3.10	 The Board, following consultation with outside counsel if deemed necessary, shall determine any measures to
address any actual or potential conflict of interest in accordance with the Board Rules. 

  

	4.	 BOARD COMMITTEES 

 

	4.1	 The Company shall procure that the Board shall have a finance and audit committee and a nomination and
compensation committee. In addition, the Board may establish more committees from time to time. The members of the nomination and compensation committee will be appointed by the shareholders’ meeting upon proposal by the Board. The members of
all other committees will be appointed by the Board. 

  

	4.2	 The Company and the SL Institutional Shareholder agree that (i) each of the Board Committees shall consist
of at least two members and (ii) the SL Institutional Shareholder has the right to nominate one director (which whilst he or she must be a member of the Board does not have to be an Institutional Shareholder Board Member nominated by the SL
Institutional Shareholder) to serve on each Board Committee (provided that the finance and audit committee shall consist only of Independent Board Members), for so long as the SL Institutional Shareholder has the right to designate at least two
persons for nomination by the Board as SL Board Members in accordance with Clause 3. As long as there is at least one 

  
 8 

 Institutional Shareholder Board Member nominated by the SL Institutional Shareholder, the SL
Institutional Shareholder shall have the right to appoint one Person to attend finance and audit committee meetings as an adviser without participating in the decision-making and voting process of the committee. The terms of appointment of such
adviser shall be determined by the Board and shall include customary confidentiality obligations but shall not entitle such adviser to any remuneration or the payment of any expenses by the Company and may provide for limitations of liability and an
indemnity no less favourable that those offered to the Board Members. 
  

	4.3	 The Parties agree that no Executive Board Member shall sit on the finance and audit committee or the nomination
and compensation committee. 

  

	5.	 INFORMATION SHARING 

 

	5.1	 The Company shall provide or procure that the SL Institutional Shareholder is promptly provided, to the extent
permitted by applicable laws and regulations, with all such information (the “Information”) in respect of any Global Blue Group company necessary in order for the SL Institutional Shareholder’s Group to: 

 

	 	(i)	 complete any tax return, compilation or filing as required by applicable law or deal with any enquiry from a
tax authority; 

  

	 	(ii)	 comply with any financial, regulatory or other reporting obligations which apply to any member of the SL
Institutional Shareholder’s Group as required by applicable law; or 

  

	 	(iii)	 comply with any other laws, rules or regulations which apply to any member of the SL Institutional
Shareholder’s Group. 

  

	5.2	 Without prejudice to the generality of Clause 5.1 above, to the extent permitted by applicable laws and
regulations and the rules and regulations of the Exchange, the Company will maintain, and will procure that each member of the Global Blue Group maintains, effective and appropriate control systems in relation to the financial, accounting and
record-keeping functions of the Global Blue Group. Each Board Member will be entitled to receive: (i) a detailed draft operating budget (including a cash flow and capital expenditure forecast) for the Global Blue Group in respect of its next
financial year, in such form as has been produced in the six months prior to the date of this Agreement, not later than twenty days before the end of each financial year; and (ii) the Management Information Package for each monthly accounting
period as soon as reasonably practicable and in any event within four weeks of the end of such period, provided that any Institutional Shareholder Board Member may at any time and from time to time notify the Company that he elects not to receive
the Management Information Package or other specified information (or to cancel or vary any such prior election). Each Institutional Shareholder Board Member will be entitled to (x) share any information received in (i) and (ii) of the
preceding sentence with the SL Institutional Shareholder; and (y) such information and such access to the officers, employees and premises of the Global Blue Group as it may reasonably require for the purposes of enabling each Institutional
Shareholder to monitor its investments in the Company, in each case for (x) and (y) for so long as the SL Institutional Shareholder’s Group holds at least 10% of the Voting Shares (from time to time). 

 

	5.3	 The Company shall procure that any document or information that is to be supplied under this Agreement which is
not in the English language is accompanied by an accurate English translation (subject to the SL Institutional Shareholder’s consent to the contrary). 

  
 9 

	5.4	 Nothing in this Agreement shall prohibit or restrict the Company from disclosing, in accordance with such laws
or applicable rules or regulations to which the Company is or becomes subject by virtue of securities of the Company being admitted to listing or trading on any stock exchange, any inside information if and when such disclosure is required under or
pursuant to the Exchange Act, or such other laws or applicable rules or regulations to which the Company is or becomes subject by virtue of securities of the Company being admitted to listing or trading on any stock exchange. 

 

	5.5	 Nothing in this Agreement shall require the Company, or any director, officer or employee of the Company, to
disclose inside information to the extent that such disclosure would violate any applicable law. The Parties acknowledge that pursuant to the Exchange Act they are prohibited from using inside information to effect transactions in Company Securities
and from disclosing inside information to third parties except as permitted by applicable laws and applicable Company policies. 

  

	5.6	 The SL Institutional Shareholder shall procure that all Information provided to it or to any member of its
Institutional Shareholder Group pursuant to Clause 3.7, Clause 4.2 or Clause 5.1 shall be treated as Confidential Information and shall be used in accordance with applicable laws and regulations. 

 

	5.7	 The SL Institutional Shareholder shall ensure that any Confidential Information it or any of its Institutional
Shareholder Board Members or any observer appointed by it pursuant to Clause 3.4 or any adviser appointed by it pursuant to Clause 4.2 receives will be treated strictly confidentially and only be disclosed: 

 

	 	(i)	 to the extent necessary to any member of its Group, and any member of its Group’s respective directors,
officers and employees, auditors, professional advisors and other representatives, on terms that such recipient shall only use such Confidential Information in connection with that Person’s legitimate interests as a shareholder or
representative or advisor of a shareholder of the Company. In no circumstances shall any such Confidential Information be shared with a company that competes with the business of the Global Blue Group (or its advisors or representatives); provided
that possession or knowledge of such Confidential Information by any member of the SL Institutional Shareholder’s Group or its designated representatives on a company’s board of directors or governing body shall not, solely for that
reason, be deemed imputed to such company; and provided further that possession or knowledge of such Confidential Information by an any member of the SL Institutional Shareholder’s Group or its representatives carrying out a central management
function with respect to a portfolio of investments, including legal, compliance, governance, audit, risk, investment committee or other oversight functions, which may include such a competing business shall not, solely for that reason, be deemed
imputed to such company where such information is not disclosed to, or used in relation to, such competing business; 

  

	 	(ii)	 to any actual or potential providers of finance to the Global Blue Group and/or any member of the SL
Institutional Shareholder’s Group and/or for the refinancing of any of the funding provided by any such finance providers provided that such finance providers are themselves subject to confidentiality obligations; 

 

	 	(iii)	 if requested or required by applicable law or by a competent court; 

 

	 	(iv)	 if requested or required by any competent securities exchange or competent regulatory or governmental body or
other authority with relevant powers to which the disclosing person is subject or submits; 

  
 10 

	 	(v)	 if necessary to enforce this Agreement in court proceedings; or 

 

	 	(vi)	 if the Company has given its written consent to disclosure. 

 

	6.	 RELATIONSHIP BETWEEN THE PARTIES 

 

	6.1	 The Company and the SL Institutional Shareholder undertake that transactions and relationships between a member
of the SL Institutional Shareholder’s Group and a member of the Global Blue Group and any agreements or arrangements between a member of the SL Institutional Shareholder’s Group and a member of the Global Blue Group will be on terms no
less favourable to the Company than those it could obtain at an arm’s length and on a customary commercial basis. 

  

	6.2	 The SL Institutional Shareholder undertakes that the voting rights attached to the Voting Shares directly or
indirectly held by it (from time to time) shall not be exercised to procure any amendment to the Articles which would be inconsistent with any of the provisions of this Agreement without the Company’s consent. 

 

	6.3	 The SL Institutional Shareholder undertakes that the voting rights attached to the Voting Shares held directly
or indirectly by it (from time to time) shall not be exercised to prejudice the Company’s suitability for becoming, or its status once it becomes, a listed company on the Exchange or the Company’s ongoing compliance with the Articles, the
applicable Exchange rules and any other laws or regulations, in each case to the extent applicable to the Company, provided that this shall not prevent any member of the SL Institutional Shareholder’s Group from: 

 

	 	(i)	 accepting a Takeover Offer; 

 

	 	(ii)	 itself making a Takeover Offer; or 

 

	 	(iii)	 selling its Voting Shares, subject to the relevant provisions of this Agreement. 

 

	7.	 TERMINATION 

  

	7.1	 This Agreement shall terminate with immediate effect upon the earlier of: 

 

	 	(i)	 the SL Institutional Shareholder’s Group ceasing to own or control, directly or indirectly, any Company
Securities; 

  

	 	(ii)	 upon mutual written consent of the Parties; and 

 

	 	(iii)	 upon the expiry of the period of 25 years from the date of Closing. 

 

	7.2	 The SL Institutional Shareholder may terminate this Agreement (with respect to itself only) with immediate
effect by written notice to the Company on or at any time after: 

  

	 	(i)	 any Person acquires or obtains Control of the Company; 

 

	 	(ii)	 the Company passes a resolution for its winding up or a court of competent jurisdiction makes an order for the
Company’s winding up or dissolution; 

  

	 	(iii)	 the commencement of any legal proceedings in relation to bankruptcy or other types of insolvency-related
reorganization proceedings of the Company, unless such proceedings are frivolous or vexatious and are discharged, stayed or dismissed within 60 calendar days of commencement; or 

  
 11 

	 	(iv)	 the Company makes an arrangement or composition with its creditors generally or makes an application to a court
of competent jurisdiction for protection from its creditors generally. 

  

	7.3	 After termination of this Agreement, all rights and obligations of the Parties under this Agreement shall end
except for this Clause 7 and Clauses 1 (Definitions and Interpretations), 5 (Information Sharing), provided that Clauses 5.1 and 5.2 shall only remain effective with respect to any reporting period during which the SL Institutional
Shareholder’s Group held Voting Shares, 9.8 (Governing Law) and 9.9 (Dispute Resolution) which will remain in full force and effect. 

  

	8.	 BUSINESS OPPORTUNITIES 

 

	8.1	 Subject to Clauses 5.6, 5.7 and 8.2, each member of the SL Institutional Shareholder’s Group and (subject
to his fiduciary duties as a director) any Institutional Shareholder Board Member may engage in or possess an interest in other investments, business ventures or entities of any nature or description, independently or with others, similar or
dissimilar to, or that compete with, the investments or any business of the Global Blue Group, and may provide advice and other assistance to any such investment, business venture or entity, and the Company shall have no rights in and to such
investments, business ventures or entities or the income or profits derived therefrom, and the pursuit of any such investment or venture, even if competitive with any business of the Global Blue Group, shall not be deemed wrongful or improper.
Neither any member of the SL Institutional Shareholder’s Group nor (subject to his fiduciary duties as a director) any Institutional Shareholder Board Member shall be obliged to present any particular investment or business opportunity to the
Company even if such opportunity is of a character that, if presented to the Company, it could be taken by any member of the Global Blue Group, and any member of the SL Institutional Shareholder’s Group and (subject to his fiduciary duties as a
director) any Institutional Shareholder Board Member shall have the right to take for its or his own account (individually or as a partner or fiduciary) or to recommend to others any such particular investment opportunity. 

 

	8.2	 Notwithstanding anything in this Clause 8 to the contrary, the SL Institutional Shareholder agrees, for itself
and on behalf of each member of the SL Institutional Shareholder’s Group, that none of them shall, without the prior written consent of the Board, use non-public information relating to the Global Blue
Group first obtained by the SL Institutional Shareholder or any member of the SL Institutional Shareholder’s Group pursuant to this Agreement other than for the purpose of exercising the SL Institutional Shareholder’s rights or monitoring
its interests as a shareholder or otherwise as permitted by Clause 5.7. 

  

	9.	 GENERAL PROVISIONS 

 

	9.1	 Scope 

Except as provided elsewhere in this Agreement, none of the provisions of this Agreement shall in any way limit (and the SL Institutional
Shareholder will not have any liability or obligations as a result of) the activities of any member of the SL Institutional Shareholder’s Group (excluding the SL Institutional Shareholder and any member of SL Institutional Shareholder Board
Member, persons appointed as observers or advisers in accordance with Clauses 3.4 or 4.2 or persons receiving Confidential Information) or as provided in Clause 8 or the activities of any portfolio company of any affiliate of any member of the SL
Institutional Shareholder’s Group. 

  
 12 

	9.2	 No recourse 

  

	 	(i)	 The parties hereby acknowledge and agree that the Ant Board Member is not an employee, agent or representative
of the SL Institutional Shareholder nor acting on behalf of the SL Institutional Shareholder in any capacity. No information received by the Ant Board Member will be imputed to the SL Institutional Shareholder and the SL Institutional Shareholder
will not be liable for any act taken by the Ant Board Member. 

  

	 	(ii)	 Notwithstanding anything that may be expressed or implied in this Agreement and to the maximum extent permitted
by applicable law, the Company covenants, agrees and acknowledges with the SL Institutional Shareholder, for itself and on behalf of each person referred to in this Clause 9.2(ii), that no recourse under this Agreement or any documents or
instruments delivered in connection with this Agreement shall be had against any member of any member of the SL Institutional Shareholder’s Group (other than the SL Institutional Shareholder) or any current or future director, officer,
employee, representative, general or limited partner of any member of the SL Institutional Shareholder’s Group, as such, whether by enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any applicable law, it
being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, representative, general or limited partner or member of the
SL Institutional Shareholder’s Group or any limited partnership or fund advised by a member of the SL Institutional Shareholder’s Group or assignee thereof or any investor in such limited partnership or fund, as such, for any obligation of
the SL Institutional Shareholder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations. The SL Institutional Shareholder shall be
entitled to enforce the provisions of this Clause 9.2(ii) against the Company on behalf of each other person referred to in this Clause 9.2(ii). The provisions of this Clause 9.2(ii) are without prejudice to any right of action the Company may have
against an Institutional Shareholder Board Member or the Ant Board Member in his or her capacity as a member of the Board or any persons appointed as observers or advisers in accordance with Clauses 3.4 or 4.2 or persons receiving Confidential
Information and in each case are without prejudice to the terms of any other agreements made with any relevant parties. 

  

	9.3	 Entire agreement 

This Agreement supersedes and terminates any preceding or concurrent oral or written agreements between the Parties and no Party shall have any
right or remedy against any other Party arising out of or in connection with any such preceding or concurrent agreements unless stated otherwise in this Agreement. 
  

	9.4	 Amendment 

This Agreement may only be amended by mutual agreement in writing. 
  

	9.5	 Assignment 

None of the Parties may assign or procure the assumption of its rights and obligations under this Agreement, either in whole or in part, to any
other Person without the prior written consent of the Company, except that the SL Institutional Shareholder may assign or procure the assumption of its rights and obligations to any of its Affiliates on giving not less than 5 Business Days’
notice to the other Parties but without the prior consent of such Parties, subject to such assignee executing a Deed of Accession in the form attached as Schedule 1 and will thereafter be deemed to be an “SL Institutional
Shareholder” and be subject to this 

  
 13 

 
Agreement as if the assignee was such assigning SL Institutional Shareholder. The preceding sentence shall not apply to a transfer of Common Shares (a) in a public offering that is
registered under the Securities Act of 1933, as amended (the “Securities Act”), (b) a transfer to one or more broker-dealers or their affiliates pursuant to a firm commitment purchase agreement for an offering that is exempt from
registration under the Securities Act, (c) a transfer made through the facilities of a registered securities exchange or automated interdealer quotation system and (d) a transfer made in compliance with the manner of sale limitations of
Rule 144(f) under the Securities Act or any successor rule or provision. 
  

	9.6	 Counterparts 

This Agreement may be signed in any number of counterparts each of which, when executed by one of the Parties, shall constitute an original.
Delivery of an executed counterpart of a signature page of this Agreement by telecopy or PDF-file shall be effective as delivery of an original counterpart of this Agreement. 

 

	9.7	 Notices 

All notices and other communications under this Agreement must be in writing in English and delivered by
e-mail to the appropriate addresses set out below, or to such addresses and as a Party may notify to the other Party from time to time. 

To the Company: 
 Jeremy
Henderson-Ross 
 General Counsel 

Global Blue Group AG 
 Route de
Crassier 7 
 1262 Eysins 

Switzerland 
 To the SL
Institutional Shareholder: 
 c/o Maples Corporate Services Limited 

PO Box 309, Ugland House 
 Grand
Cayman, KY1-1104 
 Cayman Islands 

Attention: Legal Depart. 
 Email: LegalStaff-UK@silverlake.com 
 with copies (which shall not constitute notice) to: 

c/o Silver Lake Europe LLP 

Broadbent House, 65 Grosvenor Street, 

London W1K 3LH 
 Attention: Legal
Depart. 
 Email: LegalStaff-UK@silverlake.com 

and 
 Simpson Thacher &
Bartlett LLP 
 Citypoint, One Ropemaker Street 

London EC2Y 9HU 
 Attention: Clare
Gaskell 
 Email: cgaskell@stblaw.com 

  
 14 

	9.8	 Governing law 

This Agreement shall be governed by substantive Swiss law (excluding Swiss Private International Law and international treaties, in particular
the Vienna Convention on the International Sale of Goods dated 11 April 1980). 
  

	9.9	 Dispute resolution 

Any dispute, controversy or claim arising out of or relating to this Agreement, including any question regarding its conclusion, existence,
validity, invalidity, breach, amendment or termination (each, a “Dispute”), shall be finally resolved by arbitration under Rules of Arbitration of the International Chamber of Commerce (the “ICC”) in force at the
time of such submission (the “Rules”). The Rules are deemed to be incorporated by reference into this Agreement except: (i) that any provision of such Rules relating to the appointment of an emergency arbitrator shall be
excluded in its entirety; and (ii) as may be agreed by the Parties. 
 The number of arbitrators shall be three. The Claimant(s) shall
nominate one arbitrator in the Request for Arbitration. The Respondent(s) shall nominate one arbitrator in the Answer to the Request. The two party-nominated arbitrators will then attempt to agree for a period of 30 days, in consultation with the
parties to the arbitration, upon the nomination of a third arbitrator to act as president of the tribunal, barring which the International Court of Arbitration of the ICC shall select the third arbitrator (or any arbitrator that Claimant(s) or
Respondent(s) shall fail to nominate in accordance with the foregoing). 
 The seat of arbitration shall be Zurich, Switzerland. The language
of the arbitration shall be English. 
 The arbitral proceedings shall be subject to the provisions of Chapter 12 of the Swiss Private
International Act, to the exclusion of the Third Part of the Swiss Code of Civil Procedure. 
 The Parties shall maintain strict
confidentiality with respect to all aspects of the arbitration and shall not disclose the existence of the arbitration, the arbitral proceedings, the submissions or the decisions made by the arbitral tribunal, including its awards to any non-parties or non-participants without the prior written consent of all parties to the arbitration, except to the extent: (i) required by law and applicable internal
reporting requirements; or (ii) necessary to recognize, confirm or enforce the final award in the arbitration. 
 The Parties hereby
agree that, in the event of a dispute relating to any matter contained both in this Agreement and in the Articles, the provisions of this Agreement will prevail and, in particular, the provisions of this Clause 9.9 shall take precedence over the
dispute resolution provisions in the Articles. 
 [remainder of the page intentionally left blank] 

  
 15 

	
	 THUS AGREED AND SIGNED ON THE DATE SET FORTH ABOVE
  

GLOBAL BLUE GROUP HOLDING AG

	
	 /s/ Marcel Erni

	By: Marcel Erni
	Tilte: Director

 [Signature Page to Relationship Agreement - 2(yy)] 

	
	SL GLOBETROTTER L.P.
	acting by its general partner
	SL GLOBETROTTER GP, LTD.
	
	 /s/ Joseph Osnoss

	By: Joseph Osnoss
	Title: Director

 [Signature Page to Relationship Agreement - 2(yy)] 

 SCHEDULE 1 (DEED OF ACCESSION) 

THIS DEED is made on [●] 
 BETWEEN: 

 

	(1)	 GLOBAL BLUE GROUP HOLDING AG, a limited company having its registered office in Zurichstrasse 38, 8306
Bruttisellen, Aktiengesellschaft (Neueintragung), Switzerland and identification number UID 442.546.212 (the “Company”); 

  

	(2)	 [●] (the “Assigning Shareholder”); and 

 

	(3)	 [●] (the “Acceding Company”). 

WHEREAS: 
  

	(A)	 The Company and the SL Institutional Shareholder are parties to a relationship agreement dated August
[●], 2020 (the “Relationship Agreement”). 

  

	(B)	 The Acceding Company has or will become a shareholder of the Company and wishes to enter into this deed
pursuant to Clause 9.5 of the Relationship Agreement. 

 THIS DEED WITNESSES as follows: 

Capitalised terms used in this Deed shall have the meanings ascribed to them in the Relationship Agreement, unless otherwise defined in this Deed. 

The Acceding Company confirms that it has been provided with a copy of the Relationship Agreement. 

The Acceding Company hereby undertakes to comply with the provisions of, and to perform all the obligations in, the Relationship Agreement in so far as they
are to be observed and performed by the Assigning Shareholder. The Company and the Assigning Shareholder agree that the Acceding Company will be entitled to all the rights and benefits and be subject to all the obligations of the Assigning
Shareholder under the Relationship Agreement. 
 This Deed shall be governed by substantive Swiss law (excluding Swiss Private International Law and
international treaties, in particular the Vienna Convention on the International Sale of Goods dated 11 April 1980). 
 [remainder of
the page intentionally left blank] 

	
	IN WITNESS WHEREOF this Deed has been signed on [date],
	
	[ASSIGNING SHAREHOLDER]
	
	              

	By:
	Title:
	
	[ACCEDING COMPANY]
	
	  

	By:
	Title:
	
	For acceptance and agreement:
	
	GLOBAL BLUE GROUP HOLDING AG
	
	
                     
            

	By:
	Title:EX-4.5

 Exhibit 4.5 

DIRECTOR AGREEMENT 
 Eric Meurice 

31 August 2020 
 Dear Eric 

This agreement sets out the terms under which Global Blue Group Holding AG, a company incorporated in Switzerland with registered number CHE-442.546.212 with
its registered office in Wangen-Brüttisellen, Switzerland (the “Company”) appoints you to act as a non-executive director on the board of directors
of the Company (the “Board”) (the “Appointment”). 
  

	1.	 APPOINTMENT 

  

	1.1	 The Appointment shall commence upon the Merger Effective Time (as defined in the Agreement and Plan of Merger
between, inter alia, the Company, S.L. Globetrotter L.P., Far Point Acquisition Corporation and certain members of management dated 16 January 2020) (the “Effective Date”). The Appointment shall continue, subject always
to the provisions of Clauses 1.2, 1.4 and 6.1 below, until terminated in accordance with this agreement and/or Swiss law. On the date of this agreement, you shall deliver to the Company a signed acceptance of appointment form in respect of the
Appointment and thereafter such other documentation as may be required to formalise the Appointment as a matter of Swiss law. 

  

	1.2	 This agreement is subject to the articles of association and the business rules of the Company, as adopted
and/or amended from time to time (the “Articles and Business Rules”), the Swiss Code of Obligations (the “Code”), the Swiss Ordinance against Excessive Compensation in Listed Companies and other laws and regulations
that apply to the Company from time to time. Nothing in this agreement shall be taken to exclude or vary the terms of the Articles and Business Rules as they apply to you as a director of the Company. In the event of a conflict between the terms of
this agreement and the terms of the Articles and Business Rules, the terms of the Articles and Business Rules shall apply. 

  

	1.3	 You shall comply with the rules, regulations and/or requirements of any regulatory body which regulates the
business carried out by the Company or any of its direct or indirect subsidiaries from time to time (the “Group”), including listing authorities and other regulatory authorities with whose rules, regulations and/or requirements the
Group must comply. By accepting this Appointment, you confirm that you are not subject to any restrictions which prevent you from holding office as a director of the Company. In addition, you agree to comply with any insider trading policy and/or
code of conduct of the Company as is in place from time to time. 

  

	1.4	 The Appointment shall be subject to and conditional upon your election and subsequent annual re-election by the shareholders of the Company at an annual general meeting in accordance with Swiss law. 

  

	2.	 DUTIES 

  

	2.1	 By accepting this Appointment, you confirm you are able to allocate sufficient time to discharge your
responsibilities and duties as contemplated by Swiss law and this agreement effectively. You warrant that you have declared any conflicts that are apparent at present. If you become aware of any potential conflicts of interest, these should be
disclosed to the Board as soon as you become aware of them. 

	2.2	 In connection with the Appointment, you agree that you shall join, serve and contribute as a member of the
Finance & Audit Committee of the Company and as a member of any other committee notified in writing to you by the Company. 

  

	2.3	 Your membership of the committees referred to in Clause 2.2 above shall, at all times and in all respects, be
subject to the Articles and Business Rules, the Code and other laws and regulations that apply to the Company from time to time. 

  

	3.	 EQUITY GRANTS 

 

	3.1	 For the purposes of this Clause 3, the following terms shall have the following meanings:

  

	 	(a)	 “Award Certificate” means, in respect of each RSA granted to you pursuant to this Clause 3, a
certificate setting out the terms of such RSA; 

  

	 	(b)	 “Conversion Rate” means the average of the spot exchange rate as at 5:00 pm, New York time, on
the five (5) trading days ending the trading day before the Grant Date, as published by Bloomberg (through its EURUSD CURNCY function), or any other rate as agreed in writing between you and the Company; 

 

	 	(c)	 “Grant Date” means, in respect of each RSA granted to you pursuant to this Clause 3, the date
on which such RSA is granted; 

  

	 	(d)	 “Market Value” means, on each Grant Date, an amount equal to the average mid-market price of the Shares in the period that is twenty (20) trading days prior to such Grant Date; 

  

	 	(e)	 “MIP” means the management incentive plan to be adopted by the Company on or around the
Effective Date; 

  

	 	(f)	 “MIP Document” means the plan document governing the MIP; and 

 

	 	(g)	 “Shares” means the common shares in the Company. 

 

	3.2	 On the Effective Date (and on the date falling every three years thereafter) and provided that at that time you
are still a director of the Company having been re-elected in accordance with Clause 1.4, you shall be granted a restricted stock award (“RSA”) under the MIP with a value of €80,000
(converted to US$ at the Conversion Rate) based on the Market Value of the Shares on the relevant Grant Date (provided that the Market Value for the first RSA granted to you shall be deemed to be US$10 per Share). To the extent that the calculation
of the total number of Shares subject to any RSA (as set out in this paragraph) results in a fraction of a Share, the number of Shares subject to such RSA shall be rounded down to the nearest whole number and the Fees payable to you in the relevant
year pursuant to Clause 4.1 below shall be increased by an amount equal to the Market Value of that fraction of a Share. 

  

	3.3	 The following specific terms shall apply to each RSA granted to you pursuant to Clause 3.1, and shall be
reflected in each Award Certificate: 

  

	 	(a)	 the vesting schedule in Rule 4 of the MIP shall be amended so that one third of such RSA shall vest on each of
the first, second and third anniversaries of the Grant Date; 

  
 2 

	 	(b)	 Rules 9.1 and 9.2 of the MIP Document shall be deleted in their entirety and replaced with the following:

 “If an Award Holder ceases to be an Employee due to: 

 

	 	a.	 personal incapacity due to ill-health or disability (other than as a
result of alcohol or drug dependency); 

  

	 	b.	 termination by the Company or its shareholders, other than in circumstances where such termination is due to or
preceded by any form of misconduct (in the sole opinion of the Company or its shareholders); 

  

	 	c.	 the Employer Company ceasing to be a Group Company; or 

 

	 	d.	 death, 

any unvested Tranches or portions of Tranches of the Award shall continue to Vest (in the case of the Award Holder’s death, in the Award
Holder’s personal representatives) per the vesting schedule set out in Rule 4.1 (as amended by this Award Certificate)”; and 
  

	 	(c)	 Rules 16.2(c) and 16.4(a) of the MIP Document shall be deleted in their entirety and shall not apply to you.

  

	3.4	 Save as otherwise set out in this Clause 3, each RSA shall be governed by the MIP Document. Each RSA issued to
you and any Shares issued and/or transferred pursuant to an RSA will be held by you subject to the terms of the Articles and Business Rules and any applicable laws. 

 

	3.5	 The RSA shall form part of your compensation as director of the Company. Notwithstanding anything to the
contrary herein, the value and grant of any RSA shall be subject to and conditional upon prior approval by the general meeting of shareholders of the Company of the aggregate board compensation for the respective term of office.

  

	4.	 CASH COMPENSATION 

 

	4.1	 Subject to approval in accordance with Clause 4.5, you shall be paid a total fee of €80,000 per annum
(less any applicable tax, social security or other deductions payable in respect of the €80,000 fee or any RSA granted in accordance with Clause 3) (the “Fees”) payable by or on behalf of the Company annually in respect of the
Appointment. 

  

	4.2	 If the Appointment terminates for any reason, the amount of Fees paid under Clause 4.1 shall be pro-rated to reflect the length of the Appointment in the relevant year. 

  

	4.3	 Other than as expressly set out in this agreement, you are not entitled to receive any other benefits from the
Company, and, upon the termination of the Appointment, you shall not be entitled to receive any payment or other benefit by way of compensation for loss of office, damages or otherwise, other than as provided for in Clauses 4.1 and 4.4.

  

	4.4	 The Company shall reimburse you for all reasonable, documented, out-of-pocket expenses necessarily and wholly incurred by you in the proper performance of your duties subject to you providing the Company with such receipts and other evidence of expenses as the Company may
reasonably require. 

  
 3 

	4.5	 The level and payment of Fees shall be subject to and conditional upon prior approval by the general meeting of
shareholders of the Company of the aggregate board compensation for the respective term of office. 

  

	5.	 INTELLECTUAL PROPERTY 

 

	5.1	 You hereby assign to the Company all existing and future intellectual property rights (including, without
limitation, patents, copyright and related rights) and inventions arising from your duties to the Company. You agree to execute promptly all documents and do all acts as may, in the opinion of the Company, be necessary to give effect to this Clause
5. 

  

	5.2	 You hereby waive all of your moral rights in respect of any acts of the Company or any acts of third parties
done with the Company’s authority in relation to any intellectual property which is the property of the Company. You irrevocably appoint the Company to be your agent in your name and on your behalf to execute documents, use your name and do all
things which are necessary or desirable for the Company to obtain for itself or its nominee the full benefit of this Clause 5. A certificate in writing, signed by any director or the secretary of the Company, that any instrument or act falls within
the authority conferred by this agreement shall be conclusive evidence that such is the case so far as any third party is concerned. 

  

	5.3	 You shall not be entitled to any remuneration (other than the Fees referred to above) in relation to the
assignment or transfer of rights under this Clause 5. 

  

	6.	 TERMINATION OF APPOINTMENT 

 

	6.1	 This agreement may be terminated by either party at any time with immediate effect and without cause, in
accordance with Article 404 of the Code. 

  

	6.2	 The Appointment and your office as director; 

 

	 	(a)	 shall expire and terminate with immediate effect following any annual general shareholders meeting of the
Company at which your re-election is not approved; 

  

	 	(b)	 may be terminated by you at any time by resigning, in accordance with Article 404 of the Code;

  

	 	(c)	 may be terminated by a resolution of the shareholders of the Company at any time with immediate effect and
without cause, in accordance with Article 705 of the Code; and 

  

	 	(d)	 may be suspended by the Company at any time with immediate effect and without cause, provided that the Company
immediately calls for an extraordinary meeting of the shareholders, in accordance with Article 726 of the Code. 

  

	6.3	 Upon termination of this agreement in accordance with Clause 6.1, you agree to resign from your office as a
director of the Company as soon as practicable following such termination. 

  

	6.4	 When the Appointment ceases, or at any time on the request of the Board, you shall immediately return all
documents and other property belonging to the Company or the Group which may be in your possession or under your control, and you undertake to return to the Company all such documents that may come into your possession in the future.

  

	6.5	 Clause 7.1 to 7.3 (inclusive) shall survive termination of this agreement. 

  
 4 

	7.	 NON-COMPETE AND CONFIDENTIALITY 

 

	7.1	 In consideration of the Fees and any RSA received under this agreement, you agree that at any time during the
Appointment, and for a period of one year following the termination of the Appointment for any reason, you shall not, save with the prior written consent of the Board, assume any role for, with or in connection with any business which competes or is
in competition with the Company or the Group, whether as a director, partner, employee, consultant or in any other capacity whatsoever. 

  

	7.2	 You shall not (save in the proper course of your duties, as required by law or as authorised by the Company)
use, disclose or communicate to any person (and shall use your best endeavours to prevent the use, disclosure or communication of) any trade or business secrets or confidential information of or relating to the Company or the Group (including but
not limited to details of actual or potential customers, customer identity, employees, directors, consultants, suppliers, licensors, licensees, agents, distributors, designs, existing and planned product lines, product applications, technology
underlying its products or services, trade arrangements, terms of business, customer requirements, customer lists, operating systems, sales and revenue information, marketing information or strategies, manufacturing processes, software, computer
systems, source codes, disputes, commission or bonus arrangements, pricing and fee arrangements and structures, price lists, business plans, financial information, business transactions, prospective business transactions, inventions, research and
development activities, personal or sensitive personal data and anything marked or otherwise treated as confidential) which you create, develop, receive or obtain in connection with the Appointment and shall not use to the detriment of the Company
or the Group any information relating to the Company or the Group. The restrictions in this Clause 7.2 shall continue to apply after the termination of the Appointment howsoever arising without limit in time. In addition, you shall continue to be
subject to any applicable insider trading or market abuse legislation. 

  

	7.3	 Reference to confidential information in this Clause 7 shall not include information which is in the public
domain at the time of its disclosure or which comes into the public domain after its disclosure otherwise than by reason of a breach of this agreement (and in such a case shall become non-confidential from the
time that the information comes into the public domain), information which was already demonstrably known to the receiving party at the date of disclosure and had not been received in confidence from the Company or information which is required to
be disclosed as a matter of law provided that, to the extent not prohibited by law, you shall notify and consult with the Company prior to making such disclosure. It shall include information in the public domain for so long as you are in a position
to use such information more readily than others who have not worked for the Company. 

  

	8.	 INDEMNIFICATION AND INSURANCE 

 

	8.1	 The indemnification policy adopted by the Board (the “Indemnification Policy”) shall apply to
you from the Effective Date, with respect to the Appointment. You shall also be entitled to be covered by the Company’s D&O insurance policy if, and to the extent that, it has elected to have one in place from time to time.

  

	9.	 MISCELLANEOUS 

 

	9.1	 This agreement (together with any other agreements referred to in it) contains the entire understanding between
the parties and supersedes all (if any) other subsisting agreements, arrangements and understandings (written or oral) relating to your Appointment as a non-executive director of the Company and all such other
agreements, arrangements and understandings shall be deemed to have been entirely replaced by this agreement by mutual consent. You warrant that you have not entered into this agreement in reliance on any warranty, representation or undertaking of
any nature whatsoever which is not expressly contained in or specifically incorporated in this agreement. Any amendments to this agreement shall only be valid if set out in writing and signed by the parties. 

  
 5 

	9.2	 This agreement and all matters (including, without limitation, any contractual or non-contractual obligations) arising from or connected with it are governed by, and will be construed in accordance with, Swiss law and the Swiss courts at the domicile of the Company shall have non-exclusive jurisdiction to settle all disputes arising in connection with any such matters. 

  
 6 

	This	 agreement has been executed on the date first above written. 

SIGNED by 
  

			
	/s/ Marcel
Erni                                         
               	  	Dated: 31 August 2020 

 for and on behalf of 
 GLOBAL
BLUE GROUP HOLDING AG 

  
 7 

 SIGNED by 
  

			
	/s/ Erice
Meurice                                        
                	  	Dated: 31 August 2020 

 ERIC MEURICE 

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]